Literature DB >> 10968914

Antiphospholipid antibodies and the protein C pathway.

N L Esmon1, O Safa, M D Smirnov, C T Esmon.   

Abstract

Among the mechanisms suggested for the prothrombotic activity of lupus anticoagulant and antiphospholipid antibodies is the direct inhibition of the anticoagulant activated protein C (APC) pathway. Although some pathological antibodies may be directed towards the proteins involved, we hypothesize that populations exist which selectively inhibit the APC complex as a result of differences in the phospholipid requirements of this complex as compared to those of the procoagulant complexes. The most prominent feature is the requirement for the presence of phosphatidylethanolamine in the membrane for APC anticoagulant function. This mimics the requirements for inhibitory activity of at least a subset of autoantibodies associated with thrombosis. The role of oxidation of the phospholipid in APC function and antibody reactivity is also discussed. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10968914     DOI: 10.1006/jaut.2000.0407

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  12 in total

Review 1.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Thrombolysis in antiphospholipid syndrome: current hematologic perspectives.

Authors:  René Y McNall-Knapp
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

3.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

4.  Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.

Authors:  Shruti Chaturvedi; Erin Cockrell; Ricardo Espinola; Linda Hsi; Stacey Fulton; Mohammad Khan; Liang Li; Fabio Fonseca; Suman Kundu; Keith R McCrae
Journal:  Thromb Res       Date:  2014-11-15       Impact factor: 3.944

Review 5.  Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.

Authors:  Denis Wahl; Aurélie Membre; Christine Perret-Guillaume; Véronique Regnault; Thomas Lecompte
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 6.  Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Authors:  Sinthiya Punnialingam; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

7.  Phosphatidylethanolamine at the luminal endothelial surface--implications for hemostasis and thrombotic autoimmunity.

Authors:  Clive W Wells; Paula E North; Suresh Kumar; Christine B Duris; John A McIntyre
Journal:  Clin Appl Thromb Hemost       Date:  2009-11-10       Impact factor: 2.389

8.  Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.

Authors:  V Michael Holers; Guillermina Girardi; Lian Mo; Joel M Guthridge; Hector Molina; Silvia S Pierangeli; Ricardo Espinola; Liu E Xiaowei; Dailing Mao; Christopher G Vialpando; Jane E Salmon
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

Review 9.  Basic mechanisms and pathogenesis of venous thrombosis.

Authors:  Charles T Esmon
Journal:  Blood Rev       Date:  2009-09       Impact factor: 8.250

10.  The antiphospholipid antibody syndrome: a case report.

Authors:  Henry Namme Luma; Marie-Solange Doualla; Elvis Temfack; Servais Albert Fiacre Eloumou Bagnaka; Emmanuella Wankie Mankaa; Dobgima Fofung
Journal:  Int Med Case Rep J       Date:  2012-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.